zolbetuximab   Click here for help

GtoPdb Ligand ID: 9209

Synonyms: claudiximab | GC-182 | IMAB-362 | IMAB362 | Vyloy® | zolbetuximab-clzb
Approved drug
zolbetuximab is an approved drug (Japan PMDA, EMA & FDA (2024))
Compound class: Antibody
Comment: Zolbetuximab (IMAB362) is an investigational, first-in-class monoclonal antibody targeting the cell surface molecule claudin18.2 (CLDN18.2), a pan-cancer drug target [5,9]. Claudin-18 is a tight-junction protein. Splice variant 2 is reported to be a highly selective cell lineage marker of gastric mucosal cells, and it is an active molecular target for tumour-targeted immunotherapy [1-2,4]. CLDN18.2 is retained on malignant transformation and is expressed in a significant proportion of primary gastric cancers and their metastases, and ectopic expression of CLDN18.2 is identified in distinct histologic subtypes of pancreatic (primary tumour and metastases) [10], esophageal, ovarian, and lung tumours [5]. Zolbetuximab binds to the first extracellular N-terminal domain which is unique to the CLDN18.2 splice variant [5,10].
Classification Click here for help
Compound class Antibody
Approved drug? Yes. FDA (2024)  |  EMA (2024)  |  Japan PMDA (2024)  |  China NMPA (2024)
International Nonproprietary Names Click here for help
INN number INN
10473 zolbetuximab
Synonyms Click here for help
claudiximab | GC-182 | IMAB-362 | IMAB362 | Vyloy® | zolbetuximab-clzb
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 753
Other databases
GtoPdb PubChem SID 315661285
Search PubMed clinical trials zolbetuximab
Search PubMed titles zolbetuximab
Search PubMed titles/abstracts zolbetuximab